VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

02 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

17 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces November 2023 Investor Conference Participation

08 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

02 Nov 2023 02:04:23 By Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

19 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

06 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

03 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

11 Sep 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

06 Sep 2023 01:00:00 By Nasdaq GlobeNewswire

Christina Ackermann Joins Verona Pharma as Non-Executive Director

31 Aug 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

03 Aug 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

26 Jul 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update

20 Jul 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

28 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

27 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies Healthcare Conference

24 May 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 May 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

02 May 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

25 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

10 Apr 2023 01:00:00 By Nasdaq GlobeNewswire